Why did AVXL's EPS remain stagnant in recent quarters?

The EPS of AVXL has remained stagnant in recent quarters due to a combination of factors:

1. **Revenue Recognition**: The company's revenue recognition practices, which are being investigated by the SEC, have contributed to the stagnation of its EPS. This investigation has created uncertainty around the company's financial reporting, leading to a lack of confidence in its earnings figures.
2. **Operating Expenses**: AVXL's operating expenses have been on the rise, primarily due to increased spending on research and development. For instance, the company reported an 18% increase in R&D expenses in Q1 2025 compared to the previous quarter. This increase in expenses has eaten into the company's earnings, making it difficult to achieve significant EPS growth.
3. **Market Conditions**: The biopharmaceutical market is highly competitive and subject to significant clinical and regulatory hurdles. AVXL's focus on developing drug candidates for CNS diseases, particularly Alzheimer's and Parkinson's, is an area with high uncertainty and significant costs. The company's inability to translate its research pipeline into approved drugs and revenue has impacted its earnings.

In summary, AVXL's EPS has remained stagnant due to a combination of revenue recognition issues, increased operating expenses, and challenging market conditions.